Other Clinical Trial - Ischemic Injury & Ischemic Preconditioning in

Status Completed

Clinical Trial Summary

In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise.

The following hypotheses are tested:

1. Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers.

2. Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.

Clinical Trial Description

All patients will be studied in supine position after an overnight fast, while plasma glucose levels are monitored. In the first 8 patients intravenous insulin is administered as needed, to reach target glucose levels between 5-7 mmol/l. Patients will be subjected to 10 minutes of forearm ischemia (non-dominant arm), combined with handgripping at 50% of maximal force until exhaustion. Upon reperfusion, Tc-99m-HYNIC-Annexin A5 will be injected intravenously. Targeting of annexin A5 to thenar muscle and forearm flexor muscle will be quantified as the percentage difference in radioactivity between experimental and control side. This procedure will be performed twice (randomized cross-over design), with at least 2 week interval, either with or without 10 minutes ischemia followed by 10 minutes of reperfusion prior to ischemic exercise.

Depending on the results of this study, substudies will be performed to study the effect of diazoxide (K-ATP channel opener, may mimic ischemic preconditioning), glibenclamide (K-ATP channel blocker, may inhibit ischemic preconditioning) or adenosine (infusion into brachial artery of non-dominant arm as a substitute for ischemic preconditioning). ;

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00184821
Study type	Observational
Source	Radboud University
Contact
Status	Completed
Phase	N/A
Start date	June 2004
Completion date	May 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05327348` - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery	Phase 3
Completed	`NCT00184912` - The Effect of Caffeine on Ischemic Preconditioning	N/A
Recruiting	`NCT05585255` - Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury
Completed	`NCT05598177` - Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass	Phase 4
Completed	`NCT04284592` - Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	N/A
Withdrawn	`NCT00441714` - Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise	N/A
Completed	`NCT00248040` - Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation	Phase 2
Completed	`NCT01486212` - Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers	N/A
Recruiting	`NCT06097702` - A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants	Phase 1
Completed	`NCT01073202` - Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation	N/A
Completed	`NCT00224406` - Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation	Phase 2
Completed	`NCT05246618` - FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT02118753` - The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium	N/A
Completed	`NCT01739088` - Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery	N/A
Completed	`NCT01040013` - Gut Oxygenation and Laparoscopy	Phase 2
Suspended	`NCT00184847` - Adenosine Receptors Influence Ischemia-Reperfusion Injury	N/A
Completed	`NCT01172171` - The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction	Phase 2
Completed	`NCT00457405` - Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?	Phase 4
Not yet recruiting	`NCT00691613` - Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model	N/A
Completed	`NCT03818126` - The Del Nido Versus Cold Blood Cardioplegia in Aortic Valve Replacement	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ischemic Injury and Ischemic Preconditioning in Diabetes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms